低于最佳的QLV比率可能表明需要一个左捆分支区域节奏优化的心脏再同步治疗升级
Péter Ezer1,2, Kitti Szűcs1, Réka Lukács1
1Heart Institute, Medical School, University of Pécs, 7624 Pécs, Hungary.
Journal of clinical medicine
|October 16, 2024
概括
左束枝区域节奏优化的心脏重同步治疗 (LOT-CRT) 显著改善了低于最佳的QLV比率的患者的结果. 这种新的方法提高了CRT的疗效,在精选的患者群体中比标准的双心脏CRT提供了显著的好处.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 医疗器械 医疗器械
背景情况:
- QLV比率是预测心脏再同步治疗 (CRT) 疗效的关键手术内指标.
- 低于最佳的QLV比率 (<70%) 可能会限制标准双心脏CRT (Biv-CRT) 的有效性.
研究的目的:
- 为了评估基于QLV比率的植入策略的有效性,使用左捆分支区域节奏优化的CRT (LOT-CRT).
- 为了比较LOT-CRT与标准Biv-CRT在QLV比率低于最佳的患者中.
主要方法:
- 一项对72名CRT除器候选人的观察研究,QRS持续时间≥160 ms.
- 患者被植入了Biv-CRT (最佳QLV比率≥70%) 或LOT-CRT (低于最佳QLV比率<70%).
- 随访进行了12个月,评估了QRS宽度,LVEF,NYHA类和NT-pro-BNP水平.
主要成果:
- 与Biv-CRT相比,LOT-CRT显示了QRS宽度的显著减少 (40.4 ± 14 ms与32 ± 13 ms相比).
- 在12个月后,LOT-CRT在LVEF (14.9 ± 8% vs 10.3 ± 7.4%),NYHA类和NT-pro-BNP水平上显示出卓越的改善.
- LOT-CRT的结果与Biv-CRT的结果相比,具有超优的QLV比率 (>80%).
结论:
- 基于QLV比率的植入策略对于CRT是可行的.
- LOT-CRT显著改善了QLV比率低于最佳的患者的治疗结果.
- 对于具有超优质QLV比率的Biv-CRT患者,升级到LOT-CRT可能不需要.
更多相关视频
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
429
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
14.6K
相关概念视频
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
3
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
3
01:30Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
01:29Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
01:25Dysrhythmias VI: Management of Dysrhythmias
3
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
3
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
1
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
1
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
2
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
2